
|Videos|October 17, 2014
The STRIDE Study: Concurrent vs Sequential Enzalutamide With Sipuleucel-T for mCRPC
Author(s)Daniel P. Petrylak, MD
Daniel P. Petrylak, MD, discusses the results of the phase II STRIDE study in metastatic castration-resistant prostate cancer (mCRPC).
Advertisement
Clinical Pearls
Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses the results of thephase II STRIDE studyin metastatic castration-resistant prostate cancer (mCRPC).
- The STRIDE study evaluated concurrent versus sequential enzalutamide in combination with sipuleucel-T for mCRPC.
- There was no difference seen in immune parameters when comparing early and delayed enzalutamide. The prime-boost effect was similar in the two arms.
- Anecdotally, no additive or synergistic toxicities were observed. Full toxicity data will be reported later.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
2
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5


















